EGFR and neoplasm: The results of scratch and MTT assays (Figures 6A, B) showed that EGFR knockdown enhanced the effect of sorafenib in inhibiting tumor cell migration and proliferation; migration was slower in the CDCA plus sorafenib group than in the control group and was comparable to that of cells treated with shEGFR followed by sorafenib.